Article Text
Commentary
MEK inhibition for low-grade serous ovarian cancer: are we there yet?
Statistics from Altmetric.com
You do not have access to the full text of this article, the first page of the PDF of this article appears above.
Footnotes
Twitter @marianascarant1
Contributors MS, MCM-M, and CG performed the literature searches. All authors contributed to manuscript writing and approved the final version.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests MS has received personal fees from AstraZeneca and personal fees from Merck Sharp and Dohme outside the submitted work. CG and MCM-M have nothing to disclose.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.